Funobactam - Evopoint Biosciences
Alternative Names: XNW-4107Latest Information Update: 24 Jan 2025
At a glance
- Originator Sinovent
- Developer Evopoint Biosciences
- Class Antibacterials; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Nosocomial infections
Most Recent Events
- 24 Jan 2025 Antimicrobial data from the preclinical trial in Bacterial infections presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious 2024 (ESCMID-2024)
- 29 Sep 2024 Evopoint Biosciences completes a phase-III trial in Nosocomial infections (Combination therapy) in USA, Spain, Israel, France (IV) (NCT05204563)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (IV, Infusion)